

Value IN HEALTH

VOLUME 14

NUMBER 6

SEPTEMBER/OCTOBER 2011

TABLE OF CONTENTS

ECONOMIC EVALUATION

- 793 Modelling Correlated Clinical Outcomes in Health Technology Appraisal**
David Epstein and Alex Sutton
- 800 Cost-Effectiveness of a Recommendation of Universal Mass Vaccination for Seasonal Influenza in the United States**
Karen M. Clements, Jeremy Chancellor, Kristin Nichol, Kelly DeLong, and David Thompson
- 812 Cost-Effectiveness of Implantable Defibrillators after Myocardial Infarction Based on 8-Year Follow-Up Data (MADIT II)**
Afschin Gandjour, Astrid Holler, Dipl-Ges-Ök, and Charles Christian Adarkwah
- 818 Esophageal Doppler Monitoring during Colorectal Resection Offers Cost-Effective Improvement of Hemodynamic Control**
Sergio Maeso, Daniel Callejo, Rodolfo Hernández, Juan A. Blasco, and Elena Andradas
- 827 Costs of Care for Dementia Patients in Community Setting: An Analysis for Mild and Moderate Disease Stage**
Larissa Schwarzkopf, Petra Menn, Simone Kunz, Rolf Holle, Jörg Lauterberg, Peter Marx, Hilmar Mehlig, Sonja Wunder, Reiner Leidl, Carolin Donath, and Elmar Graessel
- 836 A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer**
Bernardo Goulart and Scott Ramsey
- 846 Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib**
Roman Casciano, Maruit Chulikavit, Giuseppe Di Lorenzo, Zhimei Liu, Jean-Francois Baladi, Xufang Wang, Justin Robertson, and Lou Garrison
- 852 Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Chronic Kidney Disease Before and During Dialysis**
Stefan Vegter, Keith Tolley, Michael S. Keith, and Maarten J. Postma

CLINICAL OUTCOMES ASSESSMENT

- 859 A New Validation of the Spanish Work Productivity and Activity Impairment Questionnaire—Crohn's Disease Version**
Mercedes Vergara, Antònia Montserrat, Francesc Casellas, Albert Villoria, David Suarez, Michael Maudsley, Olga Gallardo, Elena Ricart, and Xavier Calvet
- 862 Impact of Measures to Enhance the Value of Observational Surveys in Rare Diseases: The Fabry Outcome Survey (FOS)**
Joe T.R. Clarke, Roberto Giugliani, Gere Sunder-Plassmann, Perry M. Elliott, Guillem Pintos-Morell, Elizabeth Hernberg-Ståhl, Maria Malmenäs, and Michael Beck, on behalf of the FOS Investigators

PATIENT-REPORTED OUTCOMES

- 867 Measurement Equivalence of Interactive Voice Response and Paper Versions of the EQ-5D in a Cancer Patient Sample**
J. Jason Lundy and Stephen Joel Coons

TABLE OF CONTENTS - continued

872 Differential Item Functioning in Quality of Life Measure between Children with and without Special Health-Care Needs

I-Chan Huang, Walter L. Leite, Patricia Shearer, Michael Seid, Dennis A. Revicki, and Elizabeth A. Shenkman

884 Comparison of the Underlying Constructs of the EQ-5D and Oxford Hip Score: Implications for Mapping

Mark Oppe, Nancy Devlin, and Nick Black

892 Development and Validation of the SEC-QOL Questionnaire in Women Using Contraceptive Methods

Ezequiel Pérez-Campos, Jose Luís Dueñas, Esther de la Viuda, María Ángeles Gómez, Roberto Lertxundi, Rafael Sánchez-Borrego, Ignaci Canals, Rafael Bermejo, Agnès Arbat, Xavier Badia, Núria Perulero, and Luis Ignacio Lete

900 Mapping FACT-Melanoma Quality-of-Life Scores to EQ-5D Health Utility Weights

Robert L. Askew, Richard J. Swartz, Yan Xing, Scott B. Cantor, Merrick I. Ross, Jeffrey E. Gershenswald, J. Lynn Palmer, Jeffrey E. Lee, and Janice N. Cormier

PREFERENCE-BASED ASSESSMENT

907 How Valid and Responsive Are Generic Health Status Measures, such as EQ-5D and SF-36, in Schizophrenia? A Systematic Review

Diana Papaioannou, John Brazier, and Glenys Parry

921 The Impact of a Revised EQ-5D Population Scoring on Preference-Based Utility Scores in an Inflammatory Arthritis Cohort

Roisin Adams, Benjamin M. Craig, Cathal D. Walsh, Douglas J. Veale, Barry Bresnihan, Oliver FitzGerald, and Michael Barry

928 Time Trade-Off Derived EQ-5D Weights for Australia

Rosalie Viney, Richard Norman, Madeleine T. King, Paula Cronin, Deborah J. Street, Stephanie Knox, and Julie Ratcliffe

937 Patient Preference for Latent Tuberculosis Infection Preventive Treatment: A Discrete Choice Experiment

Na Guo, Carlo A. Marra, J. Mark FitzGerald, R. Kevin Elwood, Aslam H. Anis, and Fawziah Marra

HEALTH POLICY ANALYSIS

944 Patient Access to New Cancer Drugs in the United States and Australia

Andrew Wilson and Joshua Cohen

953 Consistency between Direct and Indirect Trial Evidence: Is Direct Evidence Always More Reliable?

Jason Madan, Matt D. Stevenson, Katy L. Cooper, A.E. Ades, Sophie Whyte, and Ron Akehurst

961 Funding Linked to Ongoing Research: Impact of the Bosentan Patient Registry on Pricing in Australia

John Wlodarczyk, Christopher M. Reid, and Glen Pater

963 Errata